Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我爱科研完成签到,获得积分10
1秒前
LF-Scie完成签到,获得积分10
2秒前
lgf完成签到 ,获得积分10
3秒前
优雅的怀莲完成签到,获得积分10
4秒前
伶俐剑通完成签到 ,获得积分10
4秒前
6秒前
刘汉淼完成签到,获得积分0
6秒前
怡然绯完成签到 ,获得积分10
7秒前
lemon完成签到,获得积分10
8秒前
sara完成签到,获得积分10
8秒前
拥有两个亿的羊羊羊完成签到,获得积分10
9秒前
Rita完成签到,获得积分10
9秒前
ZaZa完成签到,获得积分10
10秒前
小曹医生完成签到,获得积分10
10秒前
科研通AI6.4应助yinyuzhi采纳,获得10
10秒前
10秒前
JJ完成签到,获得积分10
11秒前
JESSIE完成签到,获得积分10
12秒前
12秒前
感动葵阴完成签到,获得积分10
13秒前
ocean79完成签到,获得积分10
14秒前
ZC完成签到,获得积分10
15秒前
郭莹莹发布了新的文献求助10
16秒前
16秒前
烂漫的易烟完成签到 ,获得积分10
16秒前
不得了完成签到,获得积分20
17秒前
Tasia完成签到 ,获得积分10
17秒前
Yao完成签到,获得积分10
18秒前
洁净的天德完成签到,获得积分10
18秒前
尼斯卡完成签到,获得积分10
18秒前
黑猫老师完成签到 ,获得积分10
18秒前
吴旭东完成签到,获得积分10
19秒前
伶俐冷亦发布了新的文献求助10
20秒前
泽Y完成签到 ,获得积分10
20秒前
翁sir发布了新的文献求助50
20秒前
无花果应助科研通管家采纳,获得10
22秒前
华仔应助科研通管家采纳,获得10
22秒前
22秒前
jmy完成签到,获得积分10
22秒前
于际泽完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Römisch-Germanische Forschungen 1000
Social Psychology (第二版) 700
China Pluperfect I: Epistemology of Past and Outside in Chinese Art 520
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
The fast track to determining transfer functions of linear circuits: The student guide 500
The Analytical and Numerical Solution of Electric and Magnetic Fields 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7613062
求助须知:如何正确求助?哪些是违规求助? 9188409
关于积分的说明 19684085
捐赠科研通 7186276
什么是DOI,文献DOI怎么找? 3270770
关于科研通互助平台的介绍 2434319
邀请新用户注册赠送积分活动 2265669